International Asia WHO director urges use of dengvaxia vaccine against dengue fever

WHO director urges use of dengvaxia vaccine against dengue fever

With the alarming rise in dengue cases in the region, the vaccine may be the best solution against prevention though it has its own risk factors




- Advertisement -

It is now 2019, and countries have yet to determine a lasting preventive solution for dengue fever. Just in Singapore alone, more than 2,000 people have caught dengue fever since January this year. This is already more than thrice the number of cases compared to the first quarter of 2018 which had only 600 cases.

Tropical countries in the Southeast Asia and Pacific region are also prone to dengue. Dengue remains endemic in countries such as Singapore, Malaysia, the Philippines, Thailand, and even Hong Kong.

As such, the regional director of the World Health Organization (WHO) urged countries to consider implementing the dengvaxia vaccine to prevent the spread of the disease.

Dr. Takeshi Kasai, WHO regional director for Western Asia, said that “Dengue is not like in the past when you had a few cases then contained it. It is no longer that kind of disease. Dengue is now with us. It’s like seasonal influenza.”

- Advertisement -

Dr. Kasai made the announcement during a meeting with Hong Kong health officials regarding the alarming rise in dengue cases in the country, as reported by the South China Morning Post.

The US Food and Drug Administration approved the dengvaxia vaccine which aims to prevent the disease in children aged between nine and 16. The vaccine reportedly targets all strains of the tropical virus.

Dengvaxia is developed by Sanofi Pasteur, one the world’s largest multinational pharmaceutical companies.

Health experts warn that the vaccine should only be given to children “who have laboratory-confirmed previous dengue infections and who live in endemic areas.” Before they administer the vaccine, doctors and medical centres must be certain that the patient has had a previous dengue infection.

Sanofi discovered that “individuals who have never had a dengue infection before pose a significantly higher risk of a more severe form of the disease and hospitalisations with Dengvaxia than if they had not been vaccinated against dengue at all.”

The vaccine caused a panic and healthcare controversy in the Philippines where school children who were wrongly inoculated allegedly got infected with a strong strain of the virus while a number of children had died. The country has since banned the drug amidst ongoing investigations.

Dengvaxia is approved in 19 countries including Singapore. People interested in getting the vaccine should be aware that it is administered in three parts with six months between  doses./TISG

Send in your scoop to 

- Advertisement -

Kranji land ‘erroneous’ clearing: more supervision not always best solution, says Chan Chun Sing

Singapore – Processes should be streamlined and not more layers of supervision added in public service, said Trade and Industry Minister Chan Chun Sing on Friday (Feb 26) in response to the erroneous clearing of a large patch of woodland in...

National reserves: Whatever their strategic value, Singaporeans have right to know how they are managed

  The ruling People’s Action Party is weaponising knowledge of the exact amount of Singapore’s national reserves as a way of helping it stay in power. That’s unacceptable. It does not have such an in perpetuity right. One of the debates in...

Jolin Tsai’s perky butt got the internet abuzz

Taipei -- Mandopop diva Jolin Tsai isn't shy of flaunting her figure in all kinds of sexy and revealing outfits and her fans are just lapping it up. The 40-year-old singer uploaded a couple of photos from her trip to Yangmingshan...

Send in your scoop to